menu search

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
Data Presented at the 2023 American Society for Bone and Mineral Research (ASBMR) Annual Meeting BELTSVILLE, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of new preclinical data demonstrating that […] The post Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced... Read More
Posted: Oct 17 2023, 12:05
Author Name: forextv
Views: 112295

Search within

Pages Search Results: